Xolabin 7.5 Injection
By Xolabin
Rx
1 Injection in a Vial

Composition
Polymyxin B(750000units)

Manufacturer - Fusion Healthcare Pvt Ltd
Fusion House, Plot No. 22, H.No 8-2-350/B, Road No. 3, Banjara Hills, Hyderabad, Telangana-500034

Expires on or after
August, 2025

liver
Limited information is available regarding the use of Xolabin 7.5 Injection in individuals with liver disease. Therefore, it is essential to consult your doctor, especially if you have a history of liver problems, before using this medication. It is important to be cautious and disclose any liver-related issues to your healthcare provider before receiving Xolabin 7.5 Injection 1's. Consulting your doctor before starting this treatment will ensure your safety and well-being.

kidney
Limited information on using Xolabin 7.5 Injection in patients with kidney disease. Inform doctor if you have kidney problems before receiving injection.

alcohol
When taking Xolabin 7.5 Injection, it is not harmful to drink alcohol. However, it's best to ask your doctor about any potential interactions with Xolabin 7.5 Injection 1's.

driving
Xolabin 7.5 Injection can temporarily blur your vision after use. Avoid driving until your vision is clear. It is uncertain if Xolabin 7.5 Injection affects driving abilities. Drive only when fully alert.

pregnancy
Xolabin 7.5 Injection may not be safe to use during pregnancy. Studies in animals have shown potential harm to the developing baby. Your doctor will assess the risks and benefits before prescribing this medication. Consult with your doctor before using Xolabin 7.5 Injection.

breastfeeding
Xolabin 7.5 Injection appears to be safe during breastfeeding based on limited human data. Inform your doctor before using. Caution is advised when administering to lactating women.
Habit Forming | No |
Chemical Class | Polymyxins |
Therapeutic Class | OPHTHAL OTOLOGICALS |
Action Class | Cell membrane active agent |
₹3989
Inclusive of all taxes
Content verified by

Dr. Upasana Bhatia
MBBS - General Medicine
Last update on 11-Feb-2025